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Background
In recent years, tumor-initiating cells – so-called cancer 
stem cells (CSCs) – have been characterized in multiple 
cancers, including breast cancer [1]. Th  is component of 
cancer cells retains key stem cell properties, including self-
renewal (which initiates and drives tumorigenesis) and 
diﬀ   erentiation, albeit aberrant (which contributes to 
cellular heterogeneity). Moreover, CSCs are thought to be 
the seed for the distant metastasis responsible for poor 
clinical outcome [2,3]. Th   e discovery of CSCs provides an 
explanation for why cancer may be so diﬃ   cult to cure, and 
suggests new therapeutic strategies. Several studies 
demonstrate that breast CSCs are resistant to conventional 
therapeutic strategies such as radiotherapy or chemo-
therapy [2]. Neoadjuvant chemotherapy thus leads to an 
increase in breast CD24–/CD44+ or ALDHhigh CSCs and 
tumorsphere-initiating cells [4,5]. If these cells are the 
tumor root, then they are the cells to be killed.
Two approaches have been developed to design the 
best therapeutic strategies targeting CSCs. Th  e ﬁ  rst 
approach is based on targeting key pathways regulating 
CSC survival, diﬀ  erentiation, and self-renewal. Several 
master pathways (Hedgehog, NOTCH, and AKT/WNT/
β-catenin signaling) commonly involved in self-renewal 
of embryonic and adult stem cells are known to be 
deregulated in CSCs and to induce an expansion of this 
population [6]. A number of agents targeting these path-
ways are currently being tested preclinically, and some 
have entered clinical trials. Meanwhile, studies of CSC-
enriched populations using omics technologies are 
rapidly deﬁ   ning additional regulatory pathways and 
networks regulating CSC biology. We recently established 
a gene expression signature that allowed the identiﬁ  cation 
of CXCR1/IL-8 signaling as a key regulator pathway of 
breast CSC biology [7]. Utilizing a small molecule inhibi-
tor of CXCR1, repertaxin, we were able to speciﬁ  cally 
target the CSC population in human breast cancer 
xenografts, retarding tumor growth and reducing meta-
stasis [8].
The article
To identify novel drugs that target speciﬁ  cally  CSCs, 
researchers from Ciliberto’s group have privileged the 
second approach based on unbiased high-throughput 
screening (HTS) of small-molecule libraries on CSC-
enriched populations [9]. Because a tumor cell population 
could contain very few CSCs, HTS needs to be redesigned 
to speciﬁ  cally measure gene inhibition or drug eﬀ  ects on 
the CSC population.
In the MCF7 breast cancer cell line, the authors 
described a cell population staining pale toluidine blue 
(light cells) enriched in CSCs. Light cells presented an 
increase in tumorsphere-forming eﬃ   ciency  and  were 
enriched for ALDHbright cells, described to exclusively 
contain the CSC population [7]. When transplanted in 
immunodeﬁ   cient mice, light cells were highly 
tumorigenic compared with bulk MCF7 cells. Utilizing 
this experimental system, Cioce and colleagues 
performed a drug-screen assay. A total of 26 compounds 
were screened for their ability to kill speciﬁ  cally the light 
cells at a greater rate than the bulk MCF7 cells. Th  e 
screening assay identiﬁ  ed four such compounds, which 
all interfered with NF-κB signaling [9].
Abstract
Studies describing the tumor as a hierarchically 
organized cell population have changed the classical 
oncogenesis view and propose new therapeutic 
strategies. Cancer stem cells (CSCs) are thought 
to sustain tumor initiation/maintenance, therapy 
resistance, and systemic metastases. Targeting this 
tumor cell population is crucial to achieve a true 
cancer cure. A large research eff  ort is now aiming to 
develop drugs targeting CSCs, based either on a priori 
understanding of key pathways regulating CSC biology 
or on high-throughput screening to identify novel 
targets and compounds.
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Th  is unbiased drug-screen strategy on a CSC-enriched 
population was initially developed in the laboratories of 
Weinberg and Lander. Th   e model involved experimentally 
transformed HMLER breast cancer cells modiﬁ  ed  by 
shRNA-mediated inhibition of the human E-cadherin 
gene. Inhibition of E-cadherin expression induced an 
epithelial–mesenchymal transition, resulting in an 
increase in CD44high/CD24low cancer cells. A total of 32 
compounds in a library of 16,000 chemicals had selective 
toxicity for these artiﬁ   cially enriched breast CSCs. 
Among these compounds, salinomycin was the most 
potent. Th   e use of this potassium ionophore inhibitor as 
a potential cancer drug is novel and was validated in vivo 
using breast cancer cell line xenografts, with a decrease 
in tumor growth and metastasis formation [10].
A similar approach has been developed for human 
brain tumors with the establishment of several glioma 
neural stem cell lines stably enriched in CSCs. Utilizing a 
cell imaging-based chemical screen (comprising 450 US 
Food and Drug Administration-approved drugs), Dirks’ 
group identiﬁ   ed both diﬀ   erential sensitivities of CSCs 
and a common susceptibility to perturbation of serotonin 
signaling [11]. Th  ese observation suggests that CSCs 
might be highly susceptible to metabolic changes and 
may open new therapeutic possibilities.
Other than testing selective drug toxicity on an 
enriched-CSC population compared with bulk cancer 
cells, HTS can be designed to directly measure the drug 
eﬀ   ect on CSC function. Exploiting the relationship 
between neural stem cell self-renewal and neurosphere 
proliferation, a screen of more than 1,200 compounds 
identiﬁ   ed several neuromodulators as key regulators of 
stem cell biology [12]. A similar approach may be 
envisaged with tumorspheres from breast cancer cell lines.
Instead of using chemicals, RNA interference libraries 
can be screened to identify factors that control CSC 
tumorigenicity and stimulate the development of novel 
anti-CSC therapies. A recent kinome-wide RNA inter-
ference screen identiﬁ  ed factors that control the balance 
between maintenance and diﬀ  erentiation of glioblastoma 
CSCs. For example, silencing of TRRAP was described to 
increase diﬀ  erentiation of glioblastoma CSCs in vitro and 
also suppressed tumor formation in vivo [13].
In conclusion, HTS assays of CSCs provide oppor-
tunities to identify multiple compounds that could 
represent new revolutionary therapies. Because these 
novel compounds will be selected in vitro, it is crucial to 
extensively validate in vivo the selective toxicity of these 
drugs toward CSCs, utilizing primary tumor xenografts 
as a preclinical step. Moreover, serial transplantation of 
the residual cells isolated from treated tumors will be 
needed to prove the complete eradication of the tumor-
initiating cell population. If the ﬁ  shing season is oﬃ   cially 
open, the question remains how to choose the best bait. 
Developing therapeutic strategies to target CSCs will 
hence need a thorough and rigorous eﬀ   ort as many 
challenges remain to be overcome, such as the evaluation 
of drug eﬃ   ciency in cancer patients [14].
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